Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | MicrobiomeTrials
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2023-06-09Est. Completion: 2031-03
Enrollment target: 135 participants
Locations
Arizona Oncology Associates, PC-HOPE /ID# 252351, Tempe, Arizona, United States
UC Irvine Medical Center /ID# 263020, Orange, California, United States
Stanford University - Palo Alto /ID# 249683, Palo Alto, California, United States
Rocky Mountain Cancer Centers - Lone Tree /ID# 252237, Lone Tree, Colorado, United States
Northwestern University Feinberg School of Medicine /ID# 249347, Chicago, Illinois, United States
Beth Israel Deaconess Medical Center /ID# 249302, Boston, Massachusetts, United States
Rutgers Cancer Institute of New Jersey /ID# 249323, New Brunswick, New Jersey, United States
New York Oncology Hematology - Albany Cancer Center /ID# 252240, Albany, New York, United States
Northwell Health - Monter Cancer Center /ID# 250422, Lake Success, New York, United States
University of Rochester Medical Center /ID# 249324, Rochester, New York, United States
UC Health - Cincinnati /ID# 249299, Cincinnati, Ohio, United States
Oncology Assoc. of Oregon PC - WVCI and Research Ctr - Springfield /ID# 249309, Eugene, Oregon, United States
University of Pennsylvania /ID# 250341, Philadelphia, Pennsylvania, United States
Other microbiome trials you might be interested in